

## CAR T-Cell Therapy Market to Garner \$6.1 Billion by 2031 - Industry Sees Promising Growth in Coming Years

The benefits of CAR T-cell therapies over conventional drugs, include the destruction of cancer cells using patients' immune system, early recovery.

PORTLAND, OREGON, UNITED STATES, September 27, 2022 / EINPresswire.com/ -- Chimeric antigen receptor (CAR) T cell therapy treats certain cancers by converting T cells into cells that are more effective in fighting cancer. <u>CAR T-cell therapy</u> is a



new targeted approach, which involves the genetic engineering of T cells to target specific receptors on cancer cells. The advantages of CAR T-cell therapy over conventional drugs include the destruction of cancer cells using the immune system and early recovery. In addition, CAR T-cell therapy survives in the body for a long time. It has the ability to recognize and target cancer cells even if the cancer returns. Therefore, CAR T-cell therapy is used to treat lymphoma, acute lymphocytic leukemia and multiple myeloma blood cancer. Due to its distinct advantages over conventional drugs, CAR T-cell therapy products are expected to witness high adoption rates, which will eventually lead to growth in the CAR T-cell therapy market size.

Globally, the CAR T-cell therapy market share is witnessing significant growth, owing to increase in technological advancements, increase in prevalence of cancer, and favorable reimbursement policies in some countries, which are expected to create new opportunities for CAR T-Cell therapy market growth during the forecast period.

Major market players covered in the report, such as -

Autolus Bluebird Bio-Inc. Bristol-Myers Squibb Caribou Biosciences Inc. Cartesian Therapeutics Celgene Corporation Cellectis Celyad, Gilead Sciences, Inc. (Kite Pharma Inc.) Intellia Therapeutics Juno Therapeutics Merck & Co. Inc. Miltenyi Biotech Novartis AG Pfizer Inc. Sorrento Therapeutics, Inc.

Key Benefits for Stakeholders -

• The report provides quantitative analysis of market segments, current trends, strategies and potential of car t-cell therapy market research to identify potential car t-cell therapy market opportunities in genetics.

• In-depth analysis of this sector helps identify current market opportunities.

• Market analysis and information related to key drivers, restraints and opportunities are provided. • Porter's Five Forces Analysis identifies the capabilities of buyers and suppliers to enable stakeholders to make profitable business decisions and strengthen the network of buyers.

• The largest countries in each region are listed according to their contribution to the global market.

• Focusing on market players makes benchmarking easier and provides a clear understanding of the current market situation.

• The report includes regional and global car t-cell therapy market analysis, key players, market segments, application areas and Market growth strategies.

https://www.alliedmarketresearch.com/request-for-customization/17358

CAR T-cell therapy medicines help in treatment of lymphoma, acute lymphocytic leukemia, and multiple myeloma blood cancer. CAR T-cell therapy survives for a long time in the body, as it has the ability to recognize and target cancer cells even if the cancer relapses.

TABLE OF CONTENT -

CHAPTER 1 - INTRODUCTION:

1.1. Report description

1.2. Key market segments

- 1.3. List of key players profiled in the report
- 1.4. Research methodology
- 1.4.1. Secondary research
- 1.4.2. Primary research
- 1.4.3. Analyst tools & models

CHAPTER 2 - EXECUTIVE SUMMARY:

- 2.1. Key findings of the study
- 2.2. CXO Perspective

CHAPTER 3 - MARKET OVERVIEW: 3.1. Market Definition and Scope 3.2. Key Findings 3.2.1. Top investment pockets 3.2.2. Top winning strategies 3.3. Market Share Analysis/Top Player Positioning 3.4. Porter's Five Forces Analysis 3.5. Market Dynamics 3.5.1. Drivers 3.5.2. Restraints 3.5.3. Opportunities...

3.6. COVID-19 Impact Analysis on the market

Region-wise, in CAR-T cell therapy industry, North America generated higher revenue in 2021, owing to strong presence of key players and availability of approved therapeutics with higher adoption of CAR T-cell therapies. Asia-Pacific is expected to witness highest CAGR during the forecast period owing to rise in awareness regarding CAR T-cell therapy, expected launch of CART drugs, and rise in the number of target population.

0 00000000 00 0000000 0000 00000? 00000 0000: https://www.alliedmarketresearch.com/purchase-enguiry/17358

The car t-cell therapy market is expected to witness a significant growth in the coming years. This market has gained interest of the healthcare and medical sectors owing to increased prevalence of hypertension throughout the globe. Furthermore, the global car t-cell therapy market is segmented on the basis of product type, end user, and region. leading market players have been introducing various strategies to help enterprises move their on-premise models to on-demand models.

Frequently Asked Questions?

Q1. What is the total market value of car t-cell therapy market report?

Q2. Which are the top companies holding the market share in car t-cell therapy market?

Q3. Which are the largest regions for this Market?

Q4. What is the leading technology of car t-cell therapy market?

Q5. What are the major drivers for this specific Market?

Q6. What are the upcoming key trends in the car t-cell therapy market report?

About Us -

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with vario research data tables and confirms utmost accuracy in our market forecasting. Each and ever us companies and this helps us in digging out market data that helps us generate accurate y data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa Allied Analytics LLP 800-792-5285 email us here Visit us on social media: Facebook Twitter LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/593070569

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire<sup>™</sup>, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.